Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares at $58.37 ($293K) on 2026-08-17, disclosed to the SEC on 2026-08-19.
Scheduled sale ($293k) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.37 | 3,900 | $228K | 77.7% |
| 2 | $59.35 | 1,100 | $65K | 22.3% |
| Total | $58.59 avg | 5,000 | $293K | 100% |
| Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |
| ELVN | SELL | 2026-04-21 | $238K | — | Filing → |